A c-Jun N-terminal kinase inhibitor, JNK-IN-8, sensitizes triple negative breast cancer cells to lapatinib

Triple negative breast cancers (TNBC) have poor prognosis compared to other breast cancer subtypes and represent 15-20% of breast cancers diagnosed. Unique targets and new molecularly-targeted therapies are urgently needed for this subtype. Despite high expression of Epidermal Growth Factor Receptor...

Descripción completa

Detalles Bibliográficos
Autores principales: Ebelt, Nancy D., Kaoud, Tamer S., Edupuganti, Ramakrishna, Van Ravenstein, Sabrina, Dalby, Kevin N., Van Den Berg, Carla L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739608/
https://www.ncbi.nlm.nih.gov/pubmed/29285221
http://dx.doi.org/10.18632/oncotarget.20581

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739608/
https://www.ncbi.nlm.nih.gov/pubmed/29285221
http://dx.doi.org/10.18632/oncotarget.20581

Ejemplares similares